Abstract

There is increasing interest in utilizing in vitro cultures as patient avatars to develop personalized treatment for cancer. Typical cultures utilize Matrigel-coated plates and media to promote the proliferation of cancer cells as spheroids or tumor explants. However, standard culture conditions operate in large volumes and require a high concentration of cancer cells to initiate this process. Other limitations include variability in the ability to successfully establish a stable line and inconsistency in the dimensions of these microcancers for in vivo drug response measurements. This paper explored the utility of microfluidics in the cultivation of cancer cell spheroids. Six patient-derived xenograft (PDX) tumors of high-grade serous ovarian cancer were used as the source material to demonstrate that viability and epithelial marker expression in the microfluidic cultures was superior to that of Matrigel or large volume 3D cultures. To further demonstrate the potential for miniaturization and multiplexing, we fabricated multichamber microfluidic devices with integrated microvalves to enable serial seeding of several chambers followed by parallel testing of several drug concentrations. These valve-enabled microfluidic devices permitted the formation of spheroids and testing of seven drug concentrations with as few as 100,000 cancer cells per device. Overall, we demonstrate the feasibility of maintaining difficul-to-culture primary cancer cells and testing drugs in a microfluidic device. This microfluidic platform may be ideal for drug testing and personalized therapy when tumor material is limited, such as following the acquisition of biopsy specimens obtained by fine-needle aspiration.

Highlights

  • Ovarian cancer (OC) remains one of the most lethal gynecologic cancers, with 22,440 new cases and 14,080 deaths annually[1]

  • PH592 belongs to the rarer, malignant mixed mesodermal tumor (MMMT) type, which is characterized by the presence of both epithelial and mesenchymal cancer cells[36]

  • This paper demonstrates the cultivation of OC spheroids in microfluidic devices

Read more

Summary

Introduction

Ovarian cancer (OC) remains one of the most lethal gynecologic cancers, with 22,440 new cases and 14,080 deaths annually[1]. A barrier to the study of novel therapies for OC has (PDX) OC models that recapitulate patient disease in terms of histologic, genomic, transcriptomic, and therapeutic heterogeneity[4,5,6]. The responses of PDX models to standard chemotherapy, such as carboplatin and paclitaxel, parallel those observed in patients[6], PDX experiments require skilled animal technicians, higher costs, and longer timelines than in vitro studies. This motivates the need for in vitro culture systems that may be used to maintain the phenotype of primary tumors over days or weeks while testing their drug responsiveness and resistance[7,8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call